Hemab Therapeutics Targets ~$200M IPO as Clinical Programs Advance

Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG) has set terms for its initial public offering, marketing 11.8 million shares at a price range of $16 to $18, implying a deal size of approximately $200 million at the midpoint and an estimated post-offer market capitalization of roughly $667 million. The offering is being led by Goldman Sachs, Jefferies, and Evercore ISI, with Wedbush PacGrow acting as lead manager.

Hemab is a clinical-stage biotechnology company focused on developing next-generation therapies for blood coagulation disorders, targeting a range of rare but severe bleeding conditions with limited treatment options. The company’s strategy centers on building a differentiated coagulation franchise through antibody-based therapies designed to improve prophylactic treatment and reduce bleeding events across multiple indications.

The company’s lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 development for Glanzmann thrombasthenia and Phase 2 development for Factor VII deficiency—two ultra-rare disorders characterized by severe and chronic bleeding risk. Early data has demonstrated meaningful reductions in annualized treated bleed rates, including high-intensity bleed reduction, supporting advancement toward a planned Phase 3 trial expected to begin in the second half of 2026.

Hemab’s second clinical-stage program, HMB-002, is a monovalent antibody being developed for Von Willebrand Disease, the most common inherited bleeding disorder. The therapy is designed to increase endogenous levels of von Willebrand factor and Factor VIII, addressing limitations of current treatments that often require frequent intravenous administration and fail to target underlying disease biology. Initial clinical data has shown dose-dependent increases in key coagulation markers, with additional data expected in late 2026 or early 2027.

Across its pipeline, Hemab is targeting an addressable population that includes approximately 10,000 patients across its initial rare disease indications and more than 120,000 patients for Von Willebrand Disease in core geographies, with potential expansion opportunities across broader bleeding disorders. The company retains global rights to its programs and is pursuing a long-term strategy to build a leading coagulation franchise through its “2x3 by 2030” roadmap, which aims to deliver multiple commercial and late-stage assets over time.

Financially, Hemab reflects a typical clinical-stage biotech profile, with no revenue and increasing investment in development. The company reported net losses of $48.7 million in 2024 and $63.9 million in 2025, driven by rising research and development spend as programs advance through clinical trials. As of year-end 2025, Hemab held approximately $185 million in cash, which, combined with IPO proceeds, is expected to fund operations into the second half of 2028.

The IPO proceeds will primarily be used to fund continued clinical development of sutacimig and HMB-002, along with advancing earlier-stage pipeline programs and general corporate purposes.

From a positioning standpoint, Hemab enters the public markets as part of a broader wave of biotech offerings centered on targeted, mechanism-driven therapies addressing niche but high-value indications. While the company’s early clinical data and focused strategy offer upside, the story remains dependent on successful clinical execution, regulatory progression, and the ability to demonstrate durable efficacy in later-stage trials—key risks that are typical for pre-commercial biotech issuers.

Hemab is expected to price on April 30th, with trading anticipated to commence May 1st on the Nasdaq under the ticker COAG.